Inside Director Jin Yang-gon Increases Stock Holdings in HLB Therapeutics

Inside Director Jin Yang-gon of HLB Therapeutics (115450) increased his shareholding to 379,013 shares as of July 1, a 20,000-share rise from 359,013 shares as of June 10. According to the July 2 filing, Jin added shares through a June 29 intraday purchase at KRW2,229 per share. As of July 2 at 11:31 AM KST, HLB Therapeutics' stock traded at KRW2,225, down KRW50 from the previous day. Recent results show the 2025 December fiscal year-end reported total assets of KRW228.7 billion, liabilities of KRW54.8 billion, equity of KRW173.9 billion, revenue of KRW69.6 billion, operating loss of KRW3.5 billion, and net loss of KRW9.7 billion. HLB Therapeutics, a KOSDAQ-listed biotech firm since June 7, 2000, operates in the category of other specialized wholesale trade.